Advertisement

Use of Azathioprine in Multiple Sclerosis

  • R. A. C. Hughes
Conference paper

Abstract

Many arguments can be marshalled to support the use of immunosuppressive treatment in multiple sclerosis (MS)

Keywords

Multiple Sclerosis Lupus Nephritis Expand Disability Status Scale Experimental Allergic Encephalomyelitis Chronic Inflammatory Demyelinating Polyneuropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hughes RAC (1983) Immunological treatment of multiple sclerosis. J Neurol 230:73–80PubMedCrossRefGoogle Scholar
  2. 2.
    Hughes RAC (1986) Immunological treatment of multiple sclerosis. II J Neurol 233:66–68Google Scholar
  3. 3.
    Hauser SL, Dawson DM, Lehrich JR et al. (1983) Intensive immunosuppression on progressive multiple sclerosis. A randomised three-arm study of high-dose intravenous cyclophosphamide, plasma exchange and ACTH. A Engl J Med 308:173–180Google Scholar
  4. 4.
    Khatri BO, McQuillen MP, Harrington GJ et al. (1985) Chronic progressive MS: a double blind controlled study of plasmapheresis in patients taking immunosuppressive drugs. Neurology 35:312–319PubMedGoogle Scholar
  5. 5.
    Perings E, Reisert P-M, Kraft H-G (1971) Untersuchungen iiber die antiinflammatorische Wirkung von Azathioprin. Int J Clin Pharmacol 5:200–202Google Scholar
  6. 6.
    Calne RY, Murray JE (1961) Inhibition of the rejection of renal homografts in dogs by Burroughs Wellcome. Surg Forum 12:118–120PubMedGoogle Scholar
  7. 7.
    Babington RG, Medeking PW (1971) The influence of cinanserin and selected pharmacologic agents on EAE. J Pharmacol Exp Therapeutics 117:454–460Google Scholar
  8. 7a.
    Oger JJ, Antel JP, Kuo HH, Arnason BGW (1982) Influence of azathioprine (Imuran) on in vitro immune function in multiple sclerosis. Ann Neurol 11:177–181PubMedCrossRefGoogle Scholar
  9. 8.
    Hawkey CJ, Newsom-Davis J, Vincent A (1981) Plasma exchange and immunosuppressive drug treatment im myasthenia gravis: no evidence for synergy. J Neurol Neurosurg Psychiat 44:469–475PubMedCrossRefGoogle Scholar
  10. 9.
    Dyck PJ, O’Brien P, Swanson C et al. (1985) Combined azathioprine and prednisone m chromc inflammatory demyelinating polyneuropathy. Neurology 35:1173–1176PubMedGoogle Scholar
  11. 10.
    Felson DT, Anderson J (1984) Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. A Engl J Med 311:1528–1534CrossRefGoogle Scholar
  12. 11.
    Ellison GW, Myers LW (1978) Immunosuppressive drugs in multiple sclerosis: pro and con. Neurology 34:132–139Google Scholar
  13. 12.
    Millar JHD, Vas CJ, Noranha MJ et al. (1967) Long-term treatment of multiple sclerosis with corticotrophin. Lancet 2:429–431PubMedCrossRefGoogle Scholar
  14. 13.
    Mertin J (1985) Drug treatment of patients with MS. In: Koetsier JC ed. Handbook of Clinical Neurology Elsevier Sc. Publishers BV. 3:187–212Google Scholar
  15. 14.
    Frick E, Angstwurm H, Blomer R, Strauss G (1977) Immunosuppressive Thérapie Den Multiplen Sklerose. IV. Behandlungsergebnisse mit Azathioprin und Antilymphozytenglobulin. Munch Med Wochenschr 119:1111–1114Google Scholar
  16. 15.
    Mertens H-G, Dommasch D (1977) The Suppression of Experimental Allergic Encephalomyelitis and Multiple Sclerosis. In: Delmotte P, Hommes OR, and Gonsette R, eds. Belgium Ghent European Press 198–211Google Scholar
  17. 16.
    Aimard G, Confavreux C, Centre JJ et al. (1983) Etude de 213 cas de sclerose en plaques traites par l’azathioprine de 1967 a 1982. Rev Neurol 139:509–513PubMedGoogle Scholar
  18. 17.
    Lhermitte F, Marteau R, Roullet J et al. (1984) Long-term immunosuppression. Rev Neurol 140:553–558PubMedGoogle Scholar
  19. 18.
    Rosen JA (1979) Prolonged azathioprine treatment of non-remitting multiple sclerosis. J Neurol Neurosurg Psychiat 42:338–344PubMedCrossRefGoogle Scholar
  20. 19.
    Swinburn WR, Liversedge LA (1973) Azathioprine and multiple sclerosis. J Neurol Neurosurg Psychiat 36:124–126PubMedCrossRefGoogle Scholar
  21. 20.
    Mertin J, Rudge P, Kremer M et al. (1982) Double-blind controlled trial of immunosuppression in the treatment of multiple sclerosis: final report. Lancet 2:429–431Google Scholar
  22. 21.
    Patzold U, Hecker H, Pocklington K (1982) Azathioprine in treatment of multiple sclerosis. Final results of a 4½ year controlled study of its effectiveness covering 115 patients. J Neurol Sci 54:377–394Google Scholar
  23. 22.
    Ellison GW, Myers LW, Mickey MR (1986) A randomised, double-blind, placebo-controlled, variable dosage, comparative therapeutic trial of azathioprine with and without methylpred-nisolone in multiple sclerosis. Neurology 36:284Google Scholar
  24. 23.
    Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS). Neurology (Cleveland) 33:1444–1452Google Scholar
  25. 24.
    Lawson DH, Lovatt GE, Curton CS, Hennings RC, Lovatt GE (1984) Adv Drug React Ac Pois Rev 3:161–171Google Scholar
  26. 25.
    Kissel JT, Levy RJ, Mendell JR, Griggs RC (1986) Azathioprine toxicity in neuromuscular disease. Neurology 36:35–39PubMedGoogle Scholar
  27. 26.
    Kinlen LJ (1985) Incidence of cancer in rheumatoid arthritis and other disorders after immunosuppressive treatment. Amer J Med 78: suppl 13; 44–49 paPubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • R. A. C. Hughes
    • 1
  1. 1.Dept. of NeurologyUnited Medical and Dental Schools, Guy’s HospitalLondonUK

Personalised recommendations